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Introduction: Epicardial adipose tissue (EAT) is a myocardial fat from which released molecules can 
directly reach the heart. In pathological conditions, the ubiquitously tissue hypertrophy mediators are the 
exchange proteins directly activated by cAMP (EPACs), named EPAC1 and EPAC2. In the heart the main 
protective signalling against detrimental remodelling is the ST2 and IL33 molecules. ST2 exists both as 
transmembrane receptor (ST2L) and soluble (sST2) form and in  case of physiological stretch ST2L bind 
IL33 promoting anti-fibrotic signals. Contrarily in CVDs, sST2 is up regulated functioning as scavenger of 
IL33 and promoting heart dilatation. Interesting is that ST2 can be also produced by adipose tissue in normal 
condition. Due to EPACs properties to induce hyperplasia, our hypothesis  is that larger EAT cells may also 
produce sST2 that can local amplify its detrimental role on myocardium. For these reasons we want to 
verified in CVDs patients first if larger EAT cells are able to up regulate EPAC proteins and second if 
EPACs may be associate to sST2 EAT production and heart dilatation. Methods: 50 CVD patients are 
enrolled and stratified according to EAT median thickness (8mm). plasma and EAT biopsies are collected 
during surgery. Indexed left ventricular mass (hLVM), end-diastolic posterior wall (EDPW), relative wall 
thickness (RWT), left ventricular mass (LVM) values are used as cardiac dilatation indexes commonly 
approved in clinical practice. Gene expression and protein assays are performed to investigate EPACs, ST2, 
IL33 mRNA and protein production.  Results: Our data demonstrated that CVDs patients with EAT >8mm 
have significantly positive correlation with RWT and they also presented higher EPAC1 and ST2 mRNA and 
protein levels than CVDs  patients <8mm; contrarily IL33 protein is down regulated in CVDs >8mm and up-
regulated in CVDs patients < 8mm. CVDs patients with hypertrophic EAT both EPAC1 and 
EPAC2presented positive correlation with hLVM, EDPW, LVM indexes and ST2 mRNA levels. 
Conclusion: Our results demonstrated that EPACs are directly associate to EAT hyperplasia and sST2 local 
production suggesting their implication in detrimental heart hyperplasia. From these results we can suggest 
that EAT thickness can be a potential newer parameter of detrimental heart remodelling in the prevention of 
CVDs complications. 
 
